Search results
Showing 751 to 765 of 2581 results for methods
Awaiting development Reference number: GID-QS10107 Expected publication date: TBC
In development Reference number: GID-QS10188 Expected publication date: TBC
Sickle cell disease: managing acute painful episodes in hospital (CG143)
This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.
In development Reference number: GID-TA11559 Expected publication date: 10 June 2026
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
This guide describes the process NICE uses to develop NICE quality standards
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
In development Reference number: GID-TA11333 Expected publication date: TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
In development Reference number: GID-TA11669 Expected publication date: 03 September 2026
In development Reference number: GID-TA11566 Expected publication date: TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026